The Use of Canagliflozin in Diabetes Mellitus Type 2 on Renal Outcome: A Systematic Review
Introduction: One of the leading causes of death in patients with diabetes mellitus is Diabetic Kidney Disease (DKD). Canagliflozin is one of the therapeutic options that can be used to mitigate the progression of DKD. However, the limited existing studies have left the data regarding the effects of...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Faculty of Medicine, Universitas Airlangga
2024-01-01
|
| Series: | Current Internal Medicine Research and Practice Surabaya Journal |
| Subjects: | |
| Online Access: | https://e-journal.unair.ac.id/CIMRJ/article/view/50710 |
| _version_ | 1827315552832454656 |
|---|---|
| author | Vikri Haikal Soebagijo Adi Soelistijo Puspa Jongky Hendro Prajitno |
| author_facet | Vikri Haikal Soebagijo Adi Soelistijo Puspa Jongky Hendro Prajitno |
| author_sort | Vikri Haikal |
| collection | DOAJ |
| description | Introduction: One of the leading causes of death in patients with diabetes mellitus is Diabetic Kidney Disease (DKD). Canagliflozin is one of the therapeutic options that can be used to mitigate the progression of DKD. However, the limited existing studies have left the data regarding the effects of canagliflozin on the progression of DKD still unclear. Therefore, a comprehensive study on the efficacy and safety of using canagliflozin in patients with DKD is warranted.
Methods: We performed a systematic search in the PubMed, Cochrane Library, ResearchGate, and Springer for randomized, placebo-controlled trials of the treatment of type 2 diabetes mellitus (T2DM) with canagliflozin that were published. A total of 25 journals were identified, and after excluding irrelevant studies, eighteen studies were ultimately included in this systematic review with total participants of 20,047.
Results: Canagliflozin reduces the rate of estimated glomerular filtration rate (eGFR) decline in patients with diabetes mellitus. The reduction of urinary albumin-to-creatinine ratio (UACR) level was greater in canagliflozin group than in the control group, and the progression of albuminuria was slower in the canagliflozin group than in the control group.
Conclusion: The use of Canagliflozin is considered to be one of the effective therapeutic options for kidney protection in patients with diabetes mellitus who are at risk of chronic kidney disease (CKD). |
| first_indexed | 2024-04-24T22:58:15Z |
| format | Article |
| id | doaj.art-88fc69a2130a40df9631ca76dc41aa28 |
| institution | Directory Open Access Journal |
| issn | 2721-544X |
| language | English |
| last_indexed | 2024-04-24T22:58:15Z |
| publishDate | 2024-01-01 |
| publisher | Faculty of Medicine, Universitas Airlangga |
| record_format | Article |
| series | Current Internal Medicine Research and Practice Surabaya Journal |
| spelling | doaj.art-88fc69a2130a40df9631ca76dc41aa282024-03-18T03:57:23ZengFaculty of Medicine, Universitas AirlanggaCurrent Internal Medicine Research and Practice Surabaya Journal2721-544X2024-01-015110.20473/cimrj.v5i1.5071048868The Use of Canagliflozin in Diabetes Mellitus Type 2 on Renal Outcome: A Systematic ReviewVikri Haikal0https://orcid.org/0009-0005-6208-9703Soebagijo Adi Soelistijo1https://orcid.org/0000-0002-7594-0123Puspa2https://orcid.org/0000-0003-2202-8090Jongky Hendro Prajitno3https://orcid.org/0000-0002-1650-2000Faculty of Medicine, Universitas Airlangga, SurabayaEndocrine and Metabolism Division, Department of Internal Medicine, Faculty of Medicine Airlangga University, Dr. Soetomo General Academic Hospital, Surabaya, IndonesiaDepartment of Clinical Pathology, Faculty of Medicine, Universitas Airlangga/Dr. Soetomo General Hospital, Surabaya, IndonesiaEndocrine and Metabolism Division, Department of Internal Medicine, Faculty of Medicine Airlangga University, Dr. Soetomo General Academic Hospital, Surabaya, IndonesiaIntroduction: One of the leading causes of death in patients with diabetes mellitus is Diabetic Kidney Disease (DKD). Canagliflozin is one of the therapeutic options that can be used to mitigate the progression of DKD. However, the limited existing studies have left the data regarding the effects of canagliflozin on the progression of DKD still unclear. Therefore, a comprehensive study on the efficacy and safety of using canagliflozin in patients with DKD is warranted. Methods: We performed a systematic search in the PubMed, Cochrane Library, ResearchGate, and Springer for randomized, placebo-controlled trials of the treatment of type 2 diabetes mellitus (T2DM) with canagliflozin that were published. A total of 25 journals were identified, and after excluding irrelevant studies, eighteen studies were ultimately included in this systematic review with total participants of 20,047. Results: Canagliflozin reduces the rate of estimated glomerular filtration rate (eGFR) decline in patients with diabetes mellitus. The reduction of urinary albumin-to-creatinine ratio (UACR) level was greater in canagliflozin group than in the control group, and the progression of albuminuria was slower in the canagliflozin group than in the control group. Conclusion: The use of Canagliflozin is considered to be one of the effective therapeutic options for kidney protection in patients with diabetes mellitus who are at risk of chronic kidney disease (CKD).https://e-journal.unair.ac.id/CIMRJ/article/view/50710diabetes mellituscanagliflozinkidney disease |
| spellingShingle | Vikri Haikal Soebagijo Adi Soelistijo Puspa Jongky Hendro Prajitno The Use of Canagliflozin in Diabetes Mellitus Type 2 on Renal Outcome: A Systematic Review Current Internal Medicine Research and Practice Surabaya Journal diabetes mellitus canagliflozin kidney disease |
| title | The Use of Canagliflozin in Diabetes Mellitus Type 2 on Renal Outcome: A Systematic Review |
| title_full | The Use of Canagliflozin in Diabetes Mellitus Type 2 on Renal Outcome: A Systematic Review |
| title_fullStr | The Use of Canagliflozin in Diabetes Mellitus Type 2 on Renal Outcome: A Systematic Review |
| title_full_unstemmed | The Use of Canagliflozin in Diabetes Mellitus Type 2 on Renal Outcome: A Systematic Review |
| title_short | The Use of Canagliflozin in Diabetes Mellitus Type 2 on Renal Outcome: A Systematic Review |
| title_sort | use of canagliflozin in diabetes mellitus type 2 on renal outcome a systematic review |
| topic | diabetes mellitus canagliflozin kidney disease |
| url | https://e-journal.unair.ac.id/CIMRJ/article/view/50710 |
| work_keys_str_mv | AT vikrihaikal theuseofcanagliflozinindiabetesmellitustype2onrenaloutcomeasystematicreview AT soebagijoadisoelistijo theuseofcanagliflozinindiabetesmellitustype2onrenaloutcomeasystematicreview AT puspa theuseofcanagliflozinindiabetesmellitustype2onrenaloutcomeasystematicreview AT jongkyhendroprajitno theuseofcanagliflozinindiabetesmellitustype2onrenaloutcomeasystematicreview AT vikrihaikal useofcanagliflozinindiabetesmellitustype2onrenaloutcomeasystematicreview AT soebagijoadisoelistijo useofcanagliflozinindiabetesmellitustype2onrenaloutcomeasystematicreview AT puspa useofcanagliflozinindiabetesmellitustype2onrenaloutcomeasystematicreview AT jongkyhendroprajitno useofcanagliflozinindiabetesmellitustype2onrenaloutcomeasystematicreview |